These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36999405)

  • 21. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
    Galbiatti AL; Castro R; Caldas HC; Padovani JA; Pavarino EC; Goloni-Bertollo EM
    Tumour Biol; 2013 Dec; 34(6):3765-71. PubMed ID: 23838799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
    Kodidela S; Suresh Chandra P; Dubashi B
    Eur J Clin Pharmacol; 2014 Mar; 70(3):253-60. PubMed ID: 24370659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
    Tatsumoto C; Kawakami K; Nagayama J; Kawano H
    Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
    Liao C; Nie J; Xu XJ; Zhang JY; Xu WQ; Song H; Shen HP; Shen DY; Zhao FY; Liang J; Miao J; Tang YM
    Leuk Lymphoma; 2024 Jan; 65(1):91-99. PubMed ID: 37820046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
    Zhu XJ; He XL; Wu YP; Zou RY; Li WL; Zou H; You YL; Liu H; Tian X
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):11-4. PubMed ID: 25616285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
    Cheng DH; Lu H; Zou XQ
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.
    Ramalingam R; Kaur H; Scott JX; Sneha LM; Arunkumar G; Srinivasan A; Paul SFD
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):393-400. PubMed ID: 35157101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].
    Hu WW; Nuriding H; Yan M
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):852-5. PubMed ID: 23146734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
    Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
    Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
    Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
    den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
    Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.